carbohydr
bind
profil
red
algal
lectin
kappaphycu
alvarezii
evalu
centrifug
ultrafiltrationhplc
method
use
pyridylamin
oligosaccharid
bound
exclus
high
mannos
type
nglycan
glycan
complex
type
hybrid
type
pentasaccharid
core
nglycan
lectin
exhibit
prefer
expos
man
arm
similar
manner
eucheuma
serra
agglutinin
show
variou
biolog
activ
antihiv
anticarcinogen
activ
test
antiinfluenza
viru
activ
variou
strain
includ
recent
pandem
influenza
viru
inhibit
infect
variou
influenza
strain
ec
low
nanomolar
level
immunofluoresc
microscopi
use
antiinfluenza
antibodi
demonstr
antivir
activ
exert
interfer
viru
entri
host
cell
mechan
confirm
evid
direct
bind
viral
envelop
protein
hemagglutinin
ha
use
elisa
assay
result
indic
lectin
would
use
novel
antivir
reagent
prevent
infect
high
mannos
hm
bind
algal
lectin
bluegreen
alga
cyanobacteria
marin
macroalga
promis
compound
potenti
drug
prevent
transmiss
variou
envelop
virus
human
immunodefici
viru
hiv
influenza
viru
hepat
c
viru
hcv
ebola
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
suppress
viru
infect
algal
lectin
base
specif
interact
lectin
target
glycan
viru
surfac
exampl
cyanobacteri
lectin
cyanovirinn
cvn
nostoc
ellipsosporum
scytovirin
svn
scytonema
varium
mvl
microcysti
viridi
microvirin
mvn
microcysti
aeruginosa
oaa
oscillatoria
agardhii
well
red
algal
lectin
griffithsin
griffithsia
sp
eucheuma
serra
display
strong
activ
ec
picoor
nanomolar
level
hiv
infect
specif
recognit
hm
glycan
hiv
envelop
glycoprotein
antihiv
lectin
structur
dissimilar
mode
carbohydr
bind
significantli
differ
except
oaa
recent
classifi
new
lectin
famili
howev
antihiv
lectin
sever
common
characterist
amino
acid
sequenc
redund
exclus
hm
oligosaccharid
recognit
nlink
glycan
viral
envelop
pivot
role
tertiari
structur
fold
viral
invas
suscept
cell
evas
host
immun
respons
envelop
virus
hm
type
nglycan
predominantli
present
glycoprotein
involv
interact
host
cell
hiv
surfac
mediat
viru
infect
direct
bind
receptor
heavili
glycosyl
hm
glycan
hcv
express
high
level
hm
oligosaccharid
envelop
glycoprotein
hm
glycan
major
compon
nglycan
sarscov
spike
glycoprotein
togeth
rel
abund
hm
glycan
viral
surfac
hm
glycan
locat
close
proxim
receptorbind
site
promis
attract
target
antivir
hmbind
lectin
fact
hmbind
algal
lectin
cvn
show
broad
rang
antivir
activ
variou
virus
effici
inhibit
initi
step
viru
entri
cell
prevent
establish
infect
current
grow
public
health
concern
due
emerg
new
influenza
virus
potenti
caus
pandem
recent
emerg
swineorigin
influenza
virus
rapidli
transmit
human
human
caus
global
pandem
antivir
reagent
novel
therapeut
concept
still
high
demand
control
outbreak
suffici
vaccin
suppli
alway
avail
highli
pathogen
viru
strain
avian
global
threat
recent
year
mutat
virus
result
easier
humantohuman
transmiss
becom
realiti
due
reassort
host
anim
fact
pandem
viru
report
high
genet
compat
reassort
two
virus
occur
could
creat
pandem
virus
emerg
recent
pandem
swineorigin
influenza
viru
well
ongo
threat
outbreak
highli
pathogen
influenza
virus
led
us
explor
new
antivir
agent
cours
survey
found
lectin
marin
red
alga
kappaphycu
alvarezii
strong
antiinfluenza
activ
present
studi
clarifi
defin
oligosaccharid
bind
specif
evalu
inhibitori
potenc
influenza
viru
infect
k
alvarezii
agglutinin
previous
call
eucheuma
cottonii
prepar
describ
previous
store
use
influenza
viru
vaccin
hemagglutinin
ha
b
purchas
denkaseiken
niigata
japan
oligosaccharidebind
activ
determin
use
centrifug
ultrafiltrationhplc
method
describ
previous
briefli
nm
mm
trishcl
ph
nm
pyridylamin
pa
oligosaccharid
mix
kept
room
temperatur
min
subsequ
unreact
paoligosaccharid
collect
centrifug
use
nanospin
plu
gelman
scienc
pensacola
fl
aliquot
filtrat
appli
tskgel
od
column
mm
unbound
paoligosaccharid
quantifi
amount
bound
paoligosaccharid
obtain
subtract
amount
unbound
oligosaccharid
amount
ad
oligosaccharid
determin
filtrat
reaction
solut
without
lectin
bind
activ
calcul
ratio
amount
bound
oligosaccharid
ad
oligosaccharid
follow
strain
influenza
viru
kindli
provid
evalu
antiinfluenza
activ
determin
use
neutral
red
nr
dye
uptak
assay
variou
concentr
prepar
dmem
contain
lgml
trypsin
ad
mdck
cell
cultur
micropl
cell
infect
influenza
viru
multipl
infect
approxim
infecti
particl
per
cell
incub
h
nr
dye
lgml
dmem
ad
incub
h
nr
dye
incorpor
cell
extract
cell
ad
acet
ethanol
color
intens
dye
absorb
subsequ
elut
cell
measur
use
micropl
reader
multilabel
counter
perkinelm
nm
indic
surviv
follow
viru
infect
immunofluoresc
stain
perform
visual
evalu
inhibit
viru
infect
briefli
mdck
cell
grown
cover
glass
subsequ
infect
multipl
infect
approxim
infecti
particl
per
cell
presenc
absenc
test
compound
nm
lm
amantadin
dmem
contain
lgml
trypsin
infect
h
later
infect
cell
fix
aceton
min
follow
wash
phosphat
buffer
salin
ph
pb
cell
incub
mous
monoclon
antiha
antibodi
hytest
turku
finland
h
wash
pb
cell
incub
fluorescein
isothiocyan
fitc
conjug
goat
antimous
igg
antibodi
anticorp
secondair
franc
h
pb
wash
cell
mount
use
vectashield
dapi
vector
laboratori
burlingam
ca
observ
fluorescencemicroscop
olympu
olympu
japan
bind
viral
ha
assay
use
enzymelink
immunosorb
assay
elisa
follow
one
hundr
microlit
lgml
carbon
buffer
ph
coat
elisa
plate
bd
bioscienc
bedford
left
overnight
wash
three
time
pb
contain
pbst
well
block
skim
milk
h
wash
pbst
variou
concentr
influenza
vaccin
prepar
astella
tokyo
japan
enrich
viru
ha
ad
well
incub
h
wash
pbst
well
incub
mous
antiha
monoclon
antibodi
hytest
h
follow
incub
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
antibodi
ge
healthcar
uk
h
well
wash
pbst
subsequ
tetramethylbenzidin
tmb
substrat
sigmaaldrich
saintloui
mi
ad
reaction
stop
use
tmb
stop
reagent
sigmaaldrich
absorb
nm
measur
use
micropl
reader
multilabel
counter
perkinelm
inhibit
interact
ha
yeast
mannan
determin
elisa
assay
except
variou
concentr
yeast
mannan
ad
plate
coat
prior
incub
ha
lgml
oligosaccharid
bind
specif
algal
lectin
k
alvarezii
determin
use
convent
carbohydr
bind
assay
fluorescencelabel
oligosaccharid
oligosaccharid
structur
use
studi
shown
fig
kind
paoligosaccharid
test
exclus
bound
hm
type
nglycan
no
fig
recogn
nglycan
includ
complex
type
no
hybrid
type
no
pentasaccharid
core
nglycan
fig
furthermor
oligosaccharid
glycolipid
no
exhibit
interact
lectin
exhibit
bind
prefer
expos
man
arm
hm
type
oligosaccharid
similar
manner
oaa
constitut
novel
antihiv
lectin
famili
bound
high
bind
activ
oligosaccharid
man
highli
expos
posit
antiinfluenza
viru
activ
evalu
assay
inhibit
infect
mdck
cell
use
dye
uptak
assay
ten
influenza
viru
strain
one
influenza
b
viru
strain
use
examin
effect
infect
shown
fig
strongli
inhibit
infect
influenza
viru
strain
except
earlier
laboratoryadapt
strain
inhibit
influenza
viru
infect
strainindepend
dosedepend
manner
ec
low
nanomolar
level
mostli
rang
nm
tabl
cytotox
observ
nm
highest
dose
use
experi
among
influenza
virus
test
influenza
b
sensit
exhibit
ec
nm
infect
clinic
isol
recent
pandem
swineorigin
influenza
viru
also
effici
inhibit
ec
nm
investig
whether
act
inhibitor
viru
entri
cell
presenc
viral
antigen
infect
cell
determin
presenc
absenc
use
immunofluoresc
microscopi
infect
viral
antigen
detect
antiha
monoclon
antibodi
follow
fitcconjug
second
antibodi
absenc
viru
invad
prolifer
host
cell
shown
fig
contrast
presenc
nm
viral
antigen
detect
mdck
cell
indic
clearli
inhibit
viru
entri
cell
treatment
lm
amantadin
antiinfluenza
drug
known
specif
inhibitor
viral
ion
channel
protein
entri
inhibitor
block
viru
invas
cell
fig
assess
possibl
directli
bind
oligosaccharid
envelop
glycoprotein
ha
oligosaccharid
target
viru
inactiv
perform
elisa
assay
use
influenza
vaccin
prepar
commerci
avail
vaccin
contain
ha
major
compon
shown
fig
direct
interact
ha
glycoprotein
clearli
demonstr
ha
bound
immobil
dosedepend
manner
bind
yeast
mannan
use
refer
interact
ha
inhibit
immobil
incub
yeast
mannan
bear
hm
glycan
prior
incub
ha
fig
result
indic
bind
ha
influenza
viru
hm
glycan
small
carbohydratebind
agent
target
glycan
viru
surfac
promis
potenti
viralinactiv
agent
could
use
prevent
control
viru
infect
studi
demonstr
hmbind
lectin
red
alga
k
alvarezii
show
strong
antiinfluenza
activ
broad
rang
influenza
viru
strain
includ
recent
emerg
swineorigin
influenza
virus
lectin
effici
inhibit
influenza
viru
infect
ec
low
nanomolar
level
furthermor
show
intens
activ
variou
influenza
strain
regardless
viru
subtyp
strain
intriguingli
report
recent
pandem
virus
resist
antivir
activ
hmbind
innat
immun
protein
surfact
protein
spd
mannosebind
lectin
mbl
season
strain
suscept
protein
contrast
strongli
inhibit
infect
pandem
viru
well
season
strain
although
devoid
glycosyl
site
ha
resist
strain
term
practic
applic
medicin
use
strainindepend
inhibit
might
advantag
antibodybas
medicin
suscept
antigen
drift
antigen
shift
demonstr
studi
inhibit
viru
infect
caus
prevent
viral
entri
host
cell
directli
bind
surfac
envelop
glycoprotein
ha
interact
ha
competit
inhibit
yeast
mannan
bear
hm
glycan
indic
bind
ha
via
hm
glycan
reveal
studi
hm
type
oligosaccharid
recognit
highli
specif
bind
glycan
complex
type
hybrid
type
pentasaccharid
core
nglycan
detect
report
site
hemagglutinin
subunit
exclus
occupi
hm
nglycan
although
still
unknown
determin
site
specif
attach
glycan
target
hm
glycan
bind
invari
present
ha
viru
surfac
context
number
sequon
potenti
nglycosyl
site
ha
increas
influenza
epidem
past
decad
antivir
activ
lectin
spd
shown
increas
proport
number
attach
glycan
near
receptor
bind
site
recentlyisol
strain
need
examin
effect
subtyp
oligosaccharid
bind
profil
almost
ident
e
serra
red
alga
oaa
agardhii
cyanobacterium
recent
classifi
member
new
lectin
famili
found
lower
organ
lectin
prefer
man
branch
man
pentasaccharid
core
oaa
strongli
inhibit
hiv
infect
direct
bind
hiv
envelop
glycoprotein
strong
antivir
activ
lectin
presum
due
high
bind
affin
associ
constant
level
hm
oligosaccharid
close
similar
carbohydratebind
profil
antihiv
protein
suggest
might
classifi
lectin
famili
probabl
antihiv
activ
origin
isol
red
alga
k
alvarezii
previous
call
e
cottonii
red
alga
belong
genu
eucheuma
kappaphycu
econom
import
speci
wide
cultiv
edibl
seawe
sourc
carrageenan
subtrop
coastal
area
alga
contain
abund
variou
isolectin
yield
exampl
correspond
alga
dri
weight
basi
besid
high
content
lectin
genu
fig
interact
influenza
envelop
glycoprotein
ha
direct
bind
ha
analyz
use
elisa
assay
yeast
mannan
immobil
onto
elisa
plate
incub
influenza
vaccin
contain
ha
mixtur
influenza
virus
well
incub
mous
antiha
monoclon
antibodi
h
follow
hrpconjug
goat
antimous
igg
antibodi
h
subsequ
hrp
substrat
tmb
ad
well
absorb
nm
measur
absorb
express
averag
valu
duplic
assay
b
plate
coat
incub
vari
concentr
yeast
mannan
room
temperatur
h
subsequ
plate
incub
influenza
vaccin
lgml
assay
way
eucheuma
attract
attent
algaederiv
lectin
show
variou
biolog
activ
mitogen
activ
mous
human
lymphocyt
vitro
growth
inhibit
tumor
cell
addit
antihiv
activ
therefor
alga
promis
organ
furnish
novel
biochem
activ
compound
antivir
lectin
potenti
import
pharmaceut
industri
public
health
conclus
studi
provid
first
evid
red
algal
lectin
k
alvarezii
strongli
inhibit
cell
entri
variou
influenza
virus
regardless
viru
strain
inhibit
influenza
viru
propag
directli
bind
hm
glycan
envelop
glycoprotein
ha
result
paper
indic
would
use
novel
antivir
agent
